Secondary malignancy
When a receptor is permanently blocked Or destroyed
When a gene is over stimulated
When bypass activation exist and may involve an important pathways
Addition of immunomodulator to an alkylating agent. Seems of concern
Pomalidomide
Dinaciclib
ARRY 520
For CLL
FCR remains standar of care
And bendamustne rituxan an alternative
And ibrutinib for bulky diseases
Secondary tumor produced by a known gene alteration
Should be treated
by blocking a gene within the same pathway either upstream or down
stream. Instead of using standard of care for that tumor.
In pancreatic cancers most of the intervention
Have not confronted the NF kB
Review the NOTCH pathway
Spark level associate Ted with good prognosis in pancreatic cancer
Spar level
No comments:
Post a Comment